In the authorative textbook Therapy of Skin Diseases, A Worldwide Perspective on Therapeutic Approaches and Their Molecular Basis, a reference is made to palmitoylethanolamide cream. Its indication: itch.
More specifically the textbook refers to the use of PEA cream in itch in renal diseases (uremic prurigo) , general itch, lichen simplex, prurigo nodularis and local itch.
In 2006 in a review on Itch the following remark was made, although we now know that the part refering to Cannabinoid receptors is not correct, PEA does not have any affinity for those receptors:
Endogenous cannabinoids belong to a group of fatty acid amines, the N-acetylethanolamines (NAEs), with N-arachidonoylethanolamine (anandamide) and N-palmitoylethanolamine (PEA, palmidrol, N-(2-hydroxyethyl) hexadecanamide) being the most abundant. Biochemical evidence indicates that endogenous NAEs are produced and released by animal and human neurons, and by human epidermal keratinocytes. On local application, cannabinoids have analgesic and antipruritic effects in acute pain and itch models; moreover, there is growing evidence for the suppression of itch by topical cannabinoid receptor agonists under clinical conditions.
Therapy of Skin Diseases
A Worldwide Perspective on Therapeutic Approaches and Their Molecular Basis
Krieg, Thomas; Bickers, David R.; Miyachi, Yoshiki (Eds.)
2010, XXIII, 766p.
The neurobiology of itch, by Akihiko Ikoma, Martin Steinhoff, Sonja Ständer, Gil Yosipovitch|| and Martin Schmelz: NATURE REVIEWS | NEUROSCIENCE VOLUME 7 | JULY 2006 | 535